medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2009, Number 2

<< Back

Dermatología Cosmética, Médica y Quirúrgica 2009; 7 (2)

Nail changes due to capecitabine

Chang P, Borjas LCA

Language: Spanish
References: 17
Page: 141-144
PDF size: 110.17 Kb.


ABSTRACT

We report two male patients of 68 and 72 years-old with gastric carcinoma and colon cancer treated with capecitabine, whom after their first cycle of chemotherapy presented side effects of the nails grades I and III.


REFERENCES

  1. Chang P, Samcam Navarrete ME. “Onicopatías por docetaxel”. Dermatología Cosmética, Médica y Quirúrgica 2007; 5(2): 92-95.

  2. “Skin toxicity of chemotherapy drugs”, http://dermnetnz.org/ reactions/chemotherapy-toxicity.html, consultado el 25 de noviembre de 2008.

  3. Dasanu C, Alexandrescu D, Wiernik P. “Recognizing nail and skin changes associated with chemotherapy. Resident and staff physician, 52(9), http://www.residentandstaffcom/issues/articles/2006-10_03.asp, consultado el 25 de noviembre de 2008.

  4. Chiewchanvit S, Noppakun K, Kanchanarattanakorn K. “Mucocuta - neous complications of chemotherapy in 74 patients from Maharaj Nakorn Chiang Mai Hospital”. J Med Assoc Thai 2004; 87: 508-514.

  5. Minisini AM, Tosti A, Sobrero AF. “Taxane-induced nail changes: Incidence, clinical presentation and outcome”. Ann Oncol 2003; 14(2): 333-337.

  6. Flory SM, Solimando DA Jr, Webster GF et al. “Onycholysis associated with weekly administration of paclitaxel”. Ann Pharmacotherapy 1999; 33(5): 584-586.

  7. Scotté F, Tourani JM, Banu E, Peyromaure M, Levy E, Marsan S, Magherini E, Fabre-Guillevin E, Andrieu J, Oudard S. “Taxaneinduced nail changes: Incidence, clinical presentation and outcome”. J Clin Oncol 2005; 23(19): 4424-4429.

  8. Pavithran K, Doval DC. “Nail changes due to docetaxel”. Br J Dermatol 2002; 146: 709-710.

  9. Correia O, Azevedo C, Pinto Ferreira E. “Nail changes secondary to docetaxel (taxotere)”. Dermatology, 1999; 198(3): 288-290.

  10. O’Shaughnessy J, Miles D, Vukelja S et al. “Superior survival with capecitabine plus docetaxel combination therapy in anthracyclinepretreated patients with advanced breast cancer: Phase III trial results”. J Clin Oncol 2002; 20: 2812-2823.

  11. Mackey JR, Tonkin KS, Koski SI, Scarfe AG, Smylie MG, Joy AA et al. “Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer”. Clin Breast Cancer 2004; 5: 287-292.

  12. Katzung B. Farmacología básica y terapéutica. 8a ed. México: El Manual Moderno, 2002, p. 1047.

  13. Casciato D, Lwitz B. Oncología clínica. 4a ed. Marban, 2001, p. 68.

  14. Chen GY, Chen YH, Hsu MM, Tsao CJ, Chen WC. “Onychomadesis and onycholysis associated with capecitabine”. Br J Dermatol 2001; 145: 521-522.

  15. Muñoz A, Barceló R, Rubio I, Mane JM, Ferreiro J, López-Vivanco G. “Onycholysis associated with capecitabine in combination with irinotecan in two patients with colorectal cancer”. J Natl Cancer Inst 2003; 95: 1252-1253.

  16. Tejera A, Bosch R, López N, Herrera E. “Onicólisis con exudado del hiponiquio secundaria a quimioterapia con paclitaxel y capecitabina”. Act Terap Dermatol 2008; 31: 6.

  17. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ docs/ctcaev3.pdf, p. 16, consultado el 28 de noviembre de 2008.




2020     |     www.medigraphic.com